News & Updates
Filter by Specialty:
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
In the treatment of patients with drug-resistant epilepsy associated with tuberous sclerosis complex, the antiseizure effect of cannabidiol occurs within 6–10 days, according to the results of a phase III trial. Adverse events also emerge during the first 2 weeks of the titration period, and majority of these are resolved during the 16-week treatment period.
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
28 Mar 2022
Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
Patients with childhood-onset chronic rheumatic disease (CRD) do not perform as well as their peers on grade 12 standardized testing, independent of sociodemographic and mental health comorbidities, reports a population-based retrospective cohort study.
Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
27 Mar 2022
Electronic, mobile health interventions improve JIA management
Harnessing electronic (eHealth) and mobile health (mHealth) interventions appears to be an efficient way of supplementing the management of juvenile idiopathic arthritis (JIA), as shown by the results of a systematic review and meta-analysis.
Electronic, mobile health interventions improve JIA management
22 Mar 2022
Intravenous brivaracetam safe in paediatric epilepsy
Treatment with intravenous brivaracetam is well tolerated in children with epilepsy, with a safety profile consistent with that known of the oral formulation, according to the results of a phase II study. There has been no pharmacokinetic difference observed when administered as bolus or a 15-minute infusion.
